Abstract: OBJECTIVE To compare the effectuality and safety of the moxifloxacin and levofloxacin in the treatment of respiratory tract infection. METHODS Using meta-analysis to evaluate the effectuality and safety of the moxifloxacin from the randomized controlled trai1s(RCTs) published from 1998 to 2008 in Chinese journals with RevMan 5. The control group were given levofloxacin, the outcome we compared included: total efficacy rata, bacterial eradication rates, adverse effect rates. RESULTS 18 RCTs and 1 392 patients which were included meta-analysis indicated that the total effective rate of moxifloxacin is superior to controlRR 2.24, 95% CI(1.64, 3.07); P<0.000 01; the bacterial eradication rates of moxifloxacin is superior to controlRR 2.35, 95% CI(1.58, 3.49); P<0.0001; the adverse effect rates of moxifloxacin is probablely smaller than control. CONCLUSION The effectuality of the moxifloxacin in the treatment of respiratory tract infection is better than levofloxacin. The adverse effect rates of moxifloxacin is probablely smaller than control, or no difference between the two groups.